MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm

Figures & data

Table 1 Characteristics of 119 Patients Included

Characteristic	Total N=119
Age (<60/≥60)	83/36
Sex (female /male)	68/51
Smoking (yes/no)	37/82
Xuanwei area (yes/no)	73/46
Same lobe lesions (yes/no)	53/66
Number of lesions >2 (no/yes)	92/27
Ipsilateral lung lesions (yes/no)	110/9
Sum of maximum diameters of lesions >3 cm (no/yes)	62/57
Pleural invasion (no/yes)	68/51
All lesions were GGOs (yes/no)	21/98
Mediastinal lymph node metastasis (no/yes)	94/25
Classification n (%)
Multiple primary lung cancer	52 (43.7)
Intrapulmonary metastatic cancer	23 (19.3)
Uncertain	44 (37.0)
Radical resection (yes/no)	41/78
Severe postoperative complications (no/yes)	113/6
Postoperative adjuvant treatment (yes/no)	62/57
Follow-up time (months)
Median	25.97
Range	4.27–76.53

Abbreviation: GGOs, ground glass opacities.

Figure 1 Metastasis-associated protein 1(MTA1) expression in 259 lesions of 119 patients with multifocal non-small cell lung cancers ≤3 cm. (A) The proportion of MTA1 strong positive, moderate positive and weak positive expression. (B) MTA1 negative expression in para-carcinoma lung tissue. (C) MTA1 weak positive expression. (D) MTA1 moderate positive expression. (E) MTA1 strong positive expression. (F) MTA1 cytoplasmic expression in mucinous adenocarcinoma. (G) MTA1 expression in lymphoid follicles of lymph nodes without tumor metastasis. (H) MTA1 expression in lymph nodes with tumor metastasis. (I) MTA1 expression in lung adenocarcinoma of different risk levels. **p <0.01, ***p <0.001.

Figure 2 Metastasis-associated protein 1(MTA1) expression in multiple primary lung cancers (MPLCs) and intrapulmonary metastases (IPMs) patients and its correlation with prognosis. (A) The rate of strongly positive MTA1 expression among N2-positive patients and N2-negative patients. (B) The comparison of MTA1 expression in patients with MPLCs and IPMs. (C) The disease-free survival (DFS) of patients with MPLCs and IPMs. (D) The DFS of the 119 patients in this study. (E) The DFS among the 44 patients with uncertain classification. ***p <0.001.

Table 2 Univariate and Multivariate Analysis of Factors Affecting Disease-Free Survival

Variables	Univariate			Multivariate
	HR	95% CI	p	HR	95% CI	p
Xuanwei area (yes/no)	1.867	1.057–3.295	0.031
Sex (female/male)	0.924	0.516–1.653	0.789
Age ≥60 (no/yes)	1.428	0.792–2.575	0.237
Ipsilateral lung lesions (yes/no)	3.018	1.263–7.215	0.013	3.445	1.399–8.483	0.007
Same lobe lesions (yes/no)	1.180	0.667–2.090	0.570
Number of lesions >2 (no/yes)	1.279	0.677–2.420	0.448
All lesions were GGOs (yes/no)	4.121	0.996–17.048	0.051
Sum of maximum diameters of lesions >3 cm (no/yes)	1.372	0.777–2.425	0.276
Mediastinal lymph node metastasis (no/yes)	3.058	1.730–5.405	<0.001	2.232	1.253–3.968	0.006
Pleural invasion (no/yes)	1.709	0.962–3.040	0.067
Radical resection (yes/no)	1.608	0.851–3.038	0.144
High MTA1 expression (no/yes)	9.091	2.833–29.412	<0.001	7.937	2.433–25.641	0.001
Severe postoperative complications (no/yes)	2.132	0.759–5.988	0.151
Postoperative adjuvant treatment (yes/no)	0.712	0.398–1.274	0.252

Abbreviations: HR, hazard radios; CI, confidence intervals; GGOs, ground glass opacities; MTA1, metastasis-associated protein 1.